Theo3 schreef op 14 september 2018 10:42:
ROCHE: FDA OKS DRUG FOR CHILDREN CHRONIC ARTHRITIS
Cercle Finance - 10:17
(CercleFinance.com) - The US Food and Drug Administration has approved a subcutaneous formulation of Roche's Actemra for the treatment of active systemic juvenile idiopathic arthritis, a chronic disease affecting children, the Swiss company said late on Thursday.
The FDA has approved the product for the treatment of patients of two years and above, Roche said.
Actemra can be taken alone or in combination with methotrexate, it added.
In 2011, the FDA approved the intravenous formulation of Actemra for patients of two years and above who have active systemic juvenile idiopathic arthritis.
It is estimated that juvenile idiopathic arthritis affects nearly 300,000 children in the US, of which active systemic juvenile idiopathic arthritis accounts for around 10 percent.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Product Laatst +/- +/- % Tijd
K V Roche Holding AGA 239,00 -0,70 -0,29% 10:39:44
CX
De zoveelste die deze week de goedkeuring heeft gekregen als pharming maar niet in een week zit waar alles afgekeurd wordt
P.s.
Het aandeel zakt na de goedkeuring